SCHEMBL9926464

SCHEMBL9926464

CNC(=O)Cc1ccc(Cl)cc1C

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 8/20 0.51
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
SLC6A2 P23975 2/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
GALR3 O60755 1/20 0.43
NR2F2 P24468 1/20 0.43
POLB P06746 2/20 0.43
GAA P10253 1/20 0.43
KCNH2 Q12809 1/20 0.43
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4247795 0.84 ERCC1 (0.56) P2RX7GALR3NR2F2
SCHEMBL9926531 0.83 ANO1 (0.51) P2RX7HDAC3HDAC1HDAC2HDAC6
SCHEMBL14347951 0.83 P2RX7 (0.41) P2RX7HDAC3HDAC1HDAC2HDAC6
SCHEMBL14865223 0.82 P2RX7 (0.49) P2RX7HDAC3HDAC1HDAC2HDAC6
SCHEMBL18928821 0.81 AIMP2 (0.38) P2RX7POLB
SCHEMBL9890756 0.81 SUCNR1 (0.46) SLC6A2SLC6A4SLC6A3POLBGAA
SCHEMBL30349465 0.80 RXRA (0.51) P2RX7HDAC3HDAC1HDAC2HDAC6
SCHEMBL1760088 0.80 RXRA (0.51) P2RX7HDAC3HDAC1HDAC2HDAC6
SCHEMBL8654070 0.80 P2RX7 (0.48) P2RX7HDAC3HDAC1HDAC2HDAC6
SCHEMBL8651252 0.80 SHMT1 (0.55) P2RX7HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 P2RX7 3259/4885HDAC3 1516/4885HDAC1 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.